Myocardial infarction (MI) leads to an enhanced release of endocannabinoids and a massive accumulation of neutrophils and monocytes within the ischaemic myocardium. These myeloid cells originate from haematopoietic precursors in the bone marrow and are rapidly mobilized in response to MI. We aimed to determine whether endocannabinoid signalling is involved in myeloid cell mobilization and cardiac recruitment after ischaemia onset.
Methods and results
Intravenous administration of endocannabinoid 2-arachidonoylglycerol (2-AG) into wild type (WT) C57BL6 mice induced a rapid increase of blood neutrophil and monocyte counts as measured by flow cytometry. This effect was blunted when using cannabinoid receptor 2 knockout mice. In response to MI induced in WT mice, the lipidomic analysis revealed significantly elevated plasma and cardiac levels of the endocannabinoid 2-AG 24 h after infarction, but no changes in anandamide, palmitoylethanolamide, and oleoylethanolamide. This was a consequence of an increased expression of 2-AG synthesizing enzyme diacylglycerol lipase and a decrease of metabolizing enzyme monoacylglycerol lipase (MAGL) in infarcted hearts, as determined by quantitative RT-PCR analysis. The opposite mRNA expression pattern was observed in bone marrow. Pharmacological blockade of MAGL with JZL184 and thus increased systemic 2-AG levels in WT mice subjected to MI resulted in elevated cardiac CXCL1, CXCL2, and MMP9 protein levels as well as higher cardiac neutrophil and monocyte counts 24 h after infarction compared with vehicle-treated mice. Increased post-MI inflammation in these mice led to an increased infarct size, an impaired ventricular scar formation assessed by histology and a worsened cardiac function in echocardiography evaluations up to 21 days. Likewise, JZL184-administration in a myocardial ischaemia-reperfusion model increased cardiac myeloid cell recruitment and resulted in a larger fibrotic scar size.
Introduction
The endocannabinoid system is a regulatory lipid signalling system that is involved in the homoeostatic control of many physiological processes. These include the regulation of immune cell function, which is mainly attributed to cannabinoid receptor 2 (CB2) signalling. 1 The most abundant endogenous CB2 agonist is 2-arachidonoylglycerol (2-AG), which is produced on demand from membrane phospholipids in many tissues, including bone marrow, 2 spleen, 3 blood, and heart. 4 The major biosynthesizing enzyme for 2-AG is diacylglycerol lipase (DAGL) and its metabolism to arachidonic acid and glycerol occurs through the catalytic activity of monoacylglycerol lipase (MAGL). 5 CB2 deficiency in mice (CB2 -/-) leads to exaggerated myocardial ischaemia-reperfusion injury and unfavourable post-myocardial infarction (MI) healing. [6] [7] [8] [9] The beneficial effects of CB2 signalling in this setting involve cardioprotective mechanisms as well as anti-fibrotic and anti-inflammatory effects. 6, 7, 10 CB2 is most abundantly expressed on immune cells, including myeloid cells. 1 Stimulation of CB2
has been reported to regulate leucocyte recruitment, both directly via chemoattraction and indirectly through inhibition of chemokine-induced recruitment. 11 Thus, CB2 signalling might play a dual role by either promoting local recruitment to inflammatory sites or by limiting immune cell recruitment and thus dampening an ongoing inflammatory response. MI leads to necrosis of a large number of cardiomyocytes, which induces a rapid infiltration of immune cells such as neutrophils and monocytes. Substantial progress has been made over the past few years in understanding their role in MI healing. These innate immune cells are instrumental in clearing the infarct area from tissue debris and subsequently promoting angiogenesis and fibrosis. The inflammatory response needs to be well balanced, as an excessive number, or a persistent presence of immune cells may lead to an unresolved resolution of inflammation. Consequently, the process of granulation tissue and collagen formation would be disturbed, which could promote cardiac dysfunction. 12, 13 Conversely, in the case of insufficient numbers of immune cells, infarct healing is delayed because dead cells are not removed and repair processes not properly induced. [12] [13] [14] Under homoeostatic conditions, myeloid cells are produced and stored in the bone marrow and spleen, from where they are rapidly mobilized after an acute MI. In view of a potential role of endocannabinoid signalling in leucocyte retention in the bone marrow niche, 2-AG levels have been reported to be much higher in bone marrow and spleen compared with plasma, suggesting a homoeostatic gradient. 2 On the other hand, tissue injury leads to a significant increase in blood and organ endocannabinoid levels. [15] [16] [17] Here, we studied the role of endocannabinoid 2-AG signalling in myeloid cell mobilization and recruitment during homeostasis and in response to cardiac injury in mice. Our data reveal that 2-AG induces myeloid cell mobilization into the blood, which is blunted in absence of CB2. MI increases systemic and cardiac 2-AG levels by shifting the expression profile of 2-AG biosynthesizing and degrading enzymes between bone marrow and infarcted myocardium, thereby promoting a gradient favouring myeloid cell recruitment to the injured heart. Blocking of the MAGL pathway in mice subjected to MI increased cardiac myeloid cell infiltration and inflammation, leading to increased infarct sizes, impaired cardiac wound healing, and worsened cardiac function.
Methods

Animal experiments
Female 10-12-week-old C57BL/6J (WT) and cannabinoid receptor (CB2 -/-) 18 mice (with constitutive knockout of the gene encoding CB2) were used in this study. Mice were bred and housed under controlled conditions in a 12 h light/12 h dark cycle. For leucocyte mobilization experiments under steady state, mice received intravenous injections of 10 mg/kg 2-AG (Tocris). 19 MI was induced by permanent ligation of the left anterior descending (LAD) coronary artery. Selective experiments were performed in mice subjected to transient 45 min of myocardial ischaemia followed by 24 h or 7 days of reperfusion. Sham-operated animals were submitted to the same surgical protocol as described below but without LAD occlusion. Mice were first randomized and then underwent either sham-or I/R-surgeries on the same day alternating between both surgeries to prevent any procedural or time-of-surgery bias. 
Echocardiography
Transthoracic echocardiography (ECG) was performed before and 3, 7, 14 and 21 days after MI on mildly anaesthetized spontaneously breathing mice (sedated by inhalation of 1% isoflurane, 1 L/min oxygen), using a Vevo 3100 High Resolution Imaging system (Visualsonics, Toronto, Canada). The mice were placed on a heated ECG platform and left parasternal long-axis view and left mid-papillary short-axis views were acquired in B-Mode and M-Mode, respectively. End-diastolic volumes, endsystolic volumes, stroke volumes, ejection fractions, and fractional shortening were evaluated on the left parasternal long-axis view. The left ventricular anterior wall thickness was measured on the left mid-papillary short-axis view in systole and diastole and the average between heart cycles was calculated. Vector displacement and three-dimensional wall displacement were generated and cardiac output was calculated using the Vevo software.
Infarct size and mortality
Hearts were perfused and harvested 24 h after LAD ligation and sectioned into four equal transverse slices. The slices were incubated in 2% triphenyltetrazolium chloride (TTC) solution (Sigma-Aldrich) at 37 C for 15 min and fixed overnight in 4% formol at 4 C. Images were taken at Â10 magnification, and quantification of viable (red) and infarct areas (white) was performed in a blinded manner with Image J software. Each mouse, which died after surgery prior to organ harvest underwent thoracotomy for post-mortem investigation if a cardiac rupture with intrapericardial haemorrhage had occurred.
Histology
Four-micrometre paraffin heart sections were stained with Masson's trichrome as follows: sections were rehydrated and incubated in heated Boin's solution before staining in Weigert's iron haematoxylin and Biebrich scarlet-acid fuchsin solution. After transferring to phosphotungstic/phosphomolybdic acid and subsequent staining with aniline blue, sections were dehydrated and mounted with Entellan V R (Sigma-Aldrich). Fibrosis was quantified as the relative area of blue staining (collagen) compared with the left ventricle surface, as an average of 3-4 sections per heart at the level of the papillary muscle, using ImageJ software. 20 Remnants of pericardial tissue around the heart were excluded from fibrosis quantification. The anterior wall thickness of the left ventricle was measured on Masson's trichome-stained sections as an average of 3-4 sections per heart. For Sirius Red staining of collagen, 3-4 sections per heart were incubated for 40 min with 0.1% Sirius Red (SigmaAldrich). Sections were photographed with identical exposure settings under ordinary polychromatic or polarized light microscopy. Interstitial collagen subtypes were evaluated using polarized light illumination; under this condition, thicker Type I collagen fibres appeared orange or red, whereas thinner type III collagen fibres were yellow or green. TUNEL staining was performed with paraffin-embedded heart sections to evaluate apoptosis in the infarcted area according to the manufacturer's instructions (DeadEnd TM Fluorometric TUNEL System, Promega).
Sections were counterstained with DAPI (Fluoroshield mounting medium, Abcam) and mounted with cover slip. Images (Â10 magnification fields within infarct areas, 2-3 fields per section) were taken using a Leica DM6000 microscope and the analysis was performed using the Leica Application Suite LAS V4.3 software unless otherwise indicated.
Cytokine and chemokine measurements
Plasma chemokines and cytokines were measured with ProcartaPlex TM Multiplex immunoassay (eBioscience). Troponin I levels were measured with a precoated enzyme-linked immunosorbent assay (ELISA kit, CUSABIO). CXCL12 levels in bone marrow lavage of femurs (flushed with 1 mL PBS per femur) were determined with standard ELISA (Duoset, R&D Systems). Approximately 30 mg tissue dissected from infarct areas (apex region) were lysed in protein lysis buffer (50 mM Tris, 150 mM NaCl pH 8.0, 0.1% Triton X 100, 0.5% sodium deoxycholate, supplemented with protease inhibitor cocktail, Roche) using a tissue homogenizer (TissueLyser LT, Qiagen). Finally, cardiac chemokines were measured with standard ELISA kits (Duoset, R&D Systems) and protein concentrations in cardiac lysates were determined by Bradford Coomassie brilliant blue assay (Biorad).
Blood counter
Freshly obtained EDTA blood harvested by cardiac puncture was used to analyse leucocyte counts using an animal blood counter (scil Vet ABC Hematology Analyzer).
Flow cytometry of heart and bone marrow
Hearts were harvested, perfused with saline to remove peripheral cells, minced with fine scissors, and digested with collagenase I (450 U/mL), collagenase XI (125 U/mL), hyaluronidase Type I-s (60 U/mL), and DNase (60 U/mL; Sigma-Aldrich and Worthington Biochemical Corporation) at 37 C for 1 h. Bone marrow cells were obtained by flushing femurs with 2 mL of saline and triturated through 70 lm nylon mesh strainer. The resulting single cell suspensions were centrifuged, resuspended in phosphate-buffered saline supplemented with 1% bovine serum albumin, and CD16/CD32 Fc-block and incubated with following monoclonal antibodies for 30 min at 4 C at 1/1000 dilution: anti-CD45.2
(clone 104, BD Biosciences), anti-CD11b (clone M1/70, BioLegend), anti-Ly6G (clone 1A8, BioLegend), anti-F4/80 (clone BM8, BioLegend), and isotype controls (BioLegend). Anti-CD115 (clone AFS98, BioLegend) and anti-CD206 (clone C068C2, BioLegend) were used at 1/500 dilution. Neutrophils were identified as CD45þ, CD11bþ, Ly6Gþ; blood monocytes as CD45þ, CD11bþ, Ly6G-, F4/80-, CD115þ, and further gated for Ly6C high and Ly6C low expressing subpopulations; cardiac monocytes as CD45þ, CD11bþ, Ly6G-, F4/80-, and further gated for the Ly6C high expressing subpopulation (Supplementary material online, Figure S1 ); cardiac macrophages as CD45þ, CD11bþ, Ly6G-, F4/80þ and further gated for CD206-for M1 subpopulation and CD206þ for M2 subpopulation. Data were acquired on a FACS Canto II (BD Biosciences), and analysis was performed with FloJo software (Ashland, USA).
Quantitative real time RT-PCR
Whole RNA from lysed hearts (TissueLyser LT, Qiagen) or bone marrow cells was extracted (peqGold Trifast and Total RNA kit, Peqlab) and reverse transcribed (PrimeScript TM RT reagent kit, Clontech). Real-time PCR was performed with the 7900HT Sequence Detection System (Applied Biosystems) using the KAPA PROBE FAST Universal qPCR kit (Peqlab) unless otherwise indicated and predesigned primer and probe mix (DAGL-b, Mm00523381_m1; Vcam1, Mm01320970_m1; TaqMan V R Gene Expression Assays, Life Technologies) as well as custom primers and probes (Supplementary material online, Table S1 ; Eurofins Genomics). Real time PCR analysis of Mmp9 was performed with SYBR Green Master Mix (Applied Biosystems) and custom primers (Supplementary material online, Table S1 ). Messenger RNA expression of markers of interest was normalized to hypoxanthine-guanine phosphoribosyltransferase (HPRT), and the fold induction was calculated by the comparative C t method.
Western blotting
The cardiac infarct area was excised and lysed in radio immunoprecipitation assay buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and 0.1% SDS, pH 8.0) supplemented with a protease inhibitor cocktail (Complete Mini, Roche) using a tissue homogenizer (TissueLyser LT, Qiagen). Aliquots (30 lg) of total protein were separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. After blocking for 1 h in Tris-buffered saline containing 0.1% Tween 20 and 5% skim milk (Carl Roth), membranes were probed overnight at 4 C with primary antibody against MMP-9
(R&D, MAB911; 1/2000 dilution) or 60 min for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Sigma-Aldrich, G954; 1/10000). Densitometric quantification of protein bands was performed using ImageJ software (NIH, Bethesda, MD, USA) and MMP9 expression was normalized to GAPDH. 
Endocannabinoid tissue measurements
Endocannabinoids were extracted from 100 lL of plasma or 10 mg cardiac tissue by liquid-liquid extraction, and then separated by liquid chromatography (Ultimate 3000RS, Dionex, CA, USA). Analyses were performed on a 5500 QTrap V R triple quadrupole/linear ion trap (QqQLIT) mass spectrometer equipped with a TurboIon-SprayTM interface (AB Sciex, Concord, ON, Canada). 21 ,22
Statistical analysis
Comparisons between two groups of normally distributed and not connected data were performed using the unpaired Student's t-test. Comparisons between two groups of normally distributed and connected data were performed using the paired Student's t-test. Comparisons between multiple group comparisons were performed by two-way analysis of variance (ANOVA) followed by Bonferroni post hoc test. Mortality was analysed by log-rank test. All data are expressed as mean ± SEM, and statistical analysis was performed with Prism Software (version 7; GraphPad, CA, USA). A P < 0.05 was considered significant.
Results
Endocannabinoid 2-AG induces myeloid cell mobilization into the circulation
In order to test whether an increase in circulating endocannabinoid 2-AG levels might induce myeloid cell mobilization from haematopoietic reservoirs into the circulation, we injected a bolus of 2-AG (10 mg/kg) intravenously into WT mice. The comparison of blood counts before and 2 h after 2-AG administration in same animals revealed at least two-fold higher circulating numbers of neutrophils and monocytes (both Ly6C high and Ly6C low populations) after 2-AG injection ( Figure 1) . To clarify whether the release into the blood was mediated via CB2 receptors, we repeated the same experiment in CB2 -/-mice. In support of a crucial role for CB2 signalling in myeloid cell mobilization, systemic 2-AG administration failed to increase monocyte counts and raised only 1.3-fold neutrophil counts in these mice ( Figure 1) . However, we noticed that circulating blood neutrophil counts per se were higher in CB2 -/-compared with WT mice (WT 0.78 Â 10 6 /mL ± 0.08; CB2 -/-1.21 Â 10 6 /mL ± 0.11 at baseline; P < 0.05). We hypothesized that elevated blood neutrophil counts in CB2 -/-mice at baseline might be a consequence of alterations in factors regulating homoeostatic granulocyte retention in the bone marrow. Indeed, we found slightly lower neutrophil counts in the bone marrow of CB2 -/-mice (Supplementary material online, Figure S2A ). This phenotype was accompanied by reduced bone marrow levels of CXCL12 (Supplementary material online, Figure S2B ), a chemokine released by stromal cells to retain neutrophil progenitors and mature neutrophils at their site of production. Moreover, we detected a 50% lower VCAM-1 mRNA expression in lysates of haematopoietic bone marrow cells obtained from CB2 -/-compared with WT mice (Supplementary material online, Figure S2C) . Thus, reduced expression of VCAM-1, which binds to integrins expressed by neutrophils, might contribute to enhanced neutrophil egress from the bone marrow.
MI induces an inverted expression profile of endocannabinoid synthesizing and metabolizing enzymes between bone marrow and heart
To clarify whether endocannabinoid levels might be systemically induced after MI in our mouse model, we quantified various endocannabinoids and related lipid mediators in the plasma and myocardium of noninfarcted vs. infarcted WT mice. We found that only 2-AG was up-regulated in hearts and plasma 24 h after MI, while anandamide, palmitoylethanolamide, and oleoylethanolamide were not changed (Figure 2A, B) .
We further compared tissue mRNA levels of enzymes involved in 2-AG biosynthesis and metabolism between steady state and 24 h after MI. Cardiac levels of endocannabinoid 2-AG producing enzyme DAGL-b were two-fold higher 24 h after MI compared with baseline ( Figure 2C ), whereas its bone marrow expression levels decreased ( Figure 2D) . Conversely, mRNA levels of the enzyme MAGL which metabolizes 2-AG were significantly down-regulated in ischaemic myocardium ( Figure 2C ), but massively up-regulated in the bone marrow ( Figure 2D ). Similar expression patterns were observed in CB2 -/-mice (Supplementary material online, Figure S3) . Thus, our data indicate that MI leads to an altered 2-AG gradient between bone marrow, plasma, and heart due to a modulation of tissue and plasma levels, which may promote leucocyte mobilization.
Pharmacological blockade of 2-AG metabolism enhances cardiac neutrophil and monocyte recruitment and inflammation
To further clarify the causal implication of 2-AG in post-MI myeloid cell recruitment, we treated mice with a pharmacological inhibitor of the 2-AG degrading enzyme MAGL (JZL184) or with the corresponding vehicle (DMSO) ( Figure 3A) . Blood counter analysis 24 h after MI revealed significantly higher circulating granulocyte and monocyte counts in mice receiving MAGL inhibitor compared with vehicle-treated mice ( Figure 3B) . The effect on cardiac myeloid cell infiltrates was even more impressive, revealing at least two-fold higher cardiac neutrophil and inflammatory Ly6C high monocyte counts in JZL184 compared with vehicle-treated mice ( Figure 3C) . Concomitantly, protein levels of neutrophil recruiting chemokines CXCL1 and CXCL2 within the infarcted myocardium were significantly elevated in JZL184-treated mice 24 h after MI, while levels of monocyte recruiting chemokine CCL2 were not significantly different compared with the vehicle-treated mice ( Figure 3D) . Infiltrated neutrophils release their granule proteins such as MMP9, which may further contribute to cardiac tissue damage in addition to the primary ischaemic event. In line with increased neutrophil counts in hearts of JZL184-treated mice, Western blot analysis confirmed significantly higher cardiac MMP9 protein levels at the same time point (Figure 3E, F) . The increase in cardiac cytokine levels was accompanied by increased plasma levels of the inflammatory cytokine TNFa in JZL184-treated mice 24 h after MI ( Figure 3G ), whereas CXCL1, CXCL2, and CCL2 plasma levels were not significantly higher ( Figure 3H ).
Pharmacological MAGL-inhibition increases infarct size and mortality
In agreement with enhanced inflammatory cell recruitment, mice receiving MAGL inhibitor had significantly larger infarct sizes quantified by TTC staining 24 h after permanent LAD occlusion ( Figure 4A, B) . Troponin I plasma levels 24 h after MI were not significantly different between both groups, possibly because this time point of analysis was beyond the plasma peak of this clinical marker ( Figure 4C) . Survival analysis after MI revealed a slightly higher mortality with increased incidences of Figure 2 MI inverts bone marrow and cardiac expression profiles of endocannabinoid biosynthesis and degradation pathways. Levels of anandamide (AEA), palmitoylethanolamide (PEA), oleoylethanolamine (OEA), and 2-arachidonoylglycerol (2-AG) in plasma (A) and heart (B) at steady state and 24 h after MI in WT mice. Messenger RNA levels of endocannabinoid synthesizing enzyme DAGL-b and metabolizing enzyme MAGL in heart (C) and bone marrow (D) at steady state and 24 h after MI in WT mice. Enzyme mRNA levels were normalized to HPRT and the fold change after MI compared with baseline (no MI) was calculated for each genotype. All data are expressed as mean ± SEM (n = 6-10 mice); two-way ANOVA followed by Bonferroni post hoc test (A and B) or unpaired Student's t-test (C and D); *P < 0.05; ns, not significant. 
Pharmacological MAGL-inhibition impairs ventricular remodelling 7 days after MI
To investigate the consequences of 2-AG driven inflammation on post-MI wound healing and remodelling, we subjected mice treated with either vehicle or MAGL inhibitor to permanent LAD ligation and performed analysis of hearts after 7 days. Immunhistological TUNEL staining and subsequent analysis of apoptotic cells within the infarct area showed no differences between vehicle-and JZL184-treated mice ( Figure 5A, B) . To study the effect of JZL184 treatment on cardiac fibrosis, we performed Masson's trichrome staining of infarcted hearts. JZL184-treated mice had larger ventricular scars with a significantly thinner left ventricular anterior wall thickness then vehicle-treated mice ( Figure 5C, D) . Sirius red staining and subsequent analysis of the collagen composition within in the infarcted myocardium revealed a significantly lower density of thick collagen Type I fibres in JZL184-treated mice compared with the vehicle group ( Figure 5E, F) . Larger (D) Protein levels of pro-inflammatory chemokines within the infarcted myocardium 24 h after MI (n = 8-9 mice). (E and F) Western blot analysis of cardiac MMP9 (active form) and GAPDH 24 h after MI and quantification of MMP9 band density, normalized to GAPDH and shown as arbitrary units (a.u.) relative to the vehicle group (set to 100; n = 7-8 mice). (G and H) Plasma levels of pro-inflammatory cytokines (n = 5-7) and chemokines 24 h after MI (n = 6-7 mice). Data were obtained in two independent experiments. All data are expressed as mean ± SEM; unpaired Student's t-test; *P < 0.05. 
Pharmacological MAGL-inhibition worsens cardiac function after MI
Since enhanced inflammation and impaired wound healing may have detrimental effects on post-MI outcome, we performed additional experiments to study prolonged effects of MAGL inhibition on cardiac function parameters. Echocardiographic analysis of vector displacement of ventricular walls, which indicates ventricular wall movement, appeared more reduced in JZL184-treated mice 14 days after MI ( Figure 6A ). The quantification of echocardiographic measurements revealed massively reduced ejection fractions 3-21 days post-MI in both experimental groups, with a significantly more pronounced decline in JZL184-treated mice ( Figure 6B ). In parallel, there was a continuous increase of the end-systolic and end-diastolic volumes, which was significantly more pronounced in JZL184-treated mice 14 and 21 days after MI compared with the vehicle group ( Figure 6B) . Stroke volumes and cardiac output declined to a similar extend in both groups after MI ( Figure 6B) . Heart rates after MI did not differ between both groups (Supplementary material online, Figure S4B) . Measurements of the left ventricular anterior wall thickness revealed thinner walls in the JZL184-treated mice, thereby confirming our histological findings (Supplementary material online, Figure S4C ).
Pharmacological MAGL inhibition after ischaemia-reperfusion increases cardiac myeloid cell recruitment, M1 macrophage accumulation, and ventricular fibrosis
Finally, we aimed to validate the effect of MAGL inhibition in a clinically more relevant scenario and subjected mice to transient LAD occlusion with 45 min of ischaemia and subsequent reperfusion or to corresponding sham operations ( Figure 7A ). Similar to the effects observed in the permanent occlusion model, JZL184 treatment resulted in higher numbers of neutrophils and Ly6C high monocytes recruited to the heart 24 h after ischaemia-reperfusion, whereas sham surgery did not or only minimally induce recruitment of these inflammatory myeloid cell subsets into the myocardium ( Figure 7B) . Concomitantly, plasma levels of neutrophil recruiting chemokine CXCL1 were significantly elevated in JZL184-treated mice compared with vehicle-treated mice 24 h after I/R ( Figure 7C ). In line with a more pronounced inflammatory response in these mice, cardiac MMP9 mRNA levels were also more increased at the same time point, whereas sham surgery resulted only in a minor increase of cardiac MMP9 mRNA levels ( Figure 7D) . Beyond the acute inflammatory phase 7 days after ischaemia-reperfusion, we detected significantly more macrophages, in particular of the inflammatory M1 subset, in the myocardium of JZL184-treated mice ( Figure 7E, F) . Moreover, histological analysis of infarcted hearts 7 days after ischaemia-reperfusion revealed larger ventricular scar sizes in JZL184-treated mice ( Figure 7G , H), which is in agreement with our findings in the permanent LAD occlusion model.
Discussion
Over the past few years, the bone marrow has gained increasing interest as a source of myeloid cells, which infiltrate the heart after an acute MI. Under steady state, a large pool of leucocytes is stored in the bone marrow and supplies blood leucocytes at low numbers to self-maintain their numbers in the circulation. Acute MI alters this leucocyte supply chain, leading to leucocytosis and a massive infiltration of myeloid cells into the injured myocardium. 23 Damage-associated molecular patterns derived from dying cells likely contribute to the acceleration of haematopoiesis to meet the high demand of immune cells, which are required for initiating cardiac repair. 24 Here, we identified the endocannabinoid 2-AG/CB2 axis as a crucial modulator of myeloid cell release and cardiac recruitment after MI.
In support of a role for CB2 signalling in regulating bone marrow retention of neutrophils during steady state, we report that mice lacking CB2 have significantly lower bone marrow CXCL12 and VCAM-1 expression levels. CXCL12 released by bone marrow stromal cells is an important retention factor for immature neutrophils expressing its cognate receptor CXCR4. 25 ,26 VCAM-1 in the bone marrow is expressed by stromal and endothelial cells as well as some haematopoietic cells such as macrophages. 27 Its major ligand is the integrin very late antigen 4 (VLA-4; a4b1) which is expressed by neutrophils. 28 Thus, reduced CXCL12 and VCAM-1 expression might both contribute to enhanced neutrophil egress from the bone marrow in absence of CB2 signalling. In line with the role of CB2 in regulating myeloid cell mobilization from the bone marrow, systemic endocannabinoid administration into CB2 -/-mice had only little effects on myeloid cell mobilization into the circulation, whereas 2-AG induced myeloid cell release was very pronounced in WT mice. During steady state, we found that leucocyte retention in the bone marrow is supported by high expression levels of endocannabinoid 2-AG synthesizing enzyme DAGL and low levels of its metabolizing enzyme MAGL. After MI, a dramatic change in the bone marrow expression of these enzymes occurs and in parallel 2-AG plasma levels increase, which are likely to contribute to the release of myeloid cells into the blood. In line with a previous report in an experimental model of liver injury, 29 we also observed an altered expression of endocannabinoid synthesizing and metabolizing enzymes as well as increased 2-AG levels in the injured myocardium 24 h after MI. This might be a direct effect of locally released inflammatory factors in the injured tissue. 30 Strikingly, the alterations in enzyme expression levels are much more important in the bone marrow compared with the ischaemic myocardium. Although elevations of various endocannabinoids including anandamide have been reported in cardiovascular diseases, 15, 31 we found that only 2-AG levels increased in the plasma and myocardium after acute MI. The MI-induced changes in the expression of endocannabinoid 2-AG synthesizing and metabolizing enzymes were comparable in both WT and CB2 -/-mice. Given that global CB2 deficiency per se has multiple effects on cardiac healing responses, [6] [7] [8] [9] we subsequently focused only on WT mice to study the consequences of pharmacological MAGL inhibition on acute post-MI inflammation and healing. After MI, increased sympathetic nervous system activity triggers haematopoietic stem and progenitor proliferation in the bone marrow and their release into the circulation. 32 Moreover, danger signals released from ischaemic myocardium into the circulation might contribute to an activation of the haematopoietic bone marrow niche. 33 Possibly these factors are also involved in the modulation of endocannabinoid enzyme expression and consequently endocannabinoid gradients between bone marrow, circulation, and hearts. We provided two different experimental proofs that enhanced circulating endocannabinoid levels mediate myeloid cell mobilization in WT mice. First, at steady state systemic administration of 2-AG resulted in rapid increases of circulating leucocyte counts. Second, pharmacological inhibition of 2-AG metabolizing enzyme MAGL further up-regulated MI-induced neutrophil and monocyte mobilization into the blood and their recruitment to the ischaemic heart. We validated that pharmacological MAGL inhibition at steady state resulted in approximately two-fold increased plasma 2-AG levels (data not shown), which are approximately in the range of the levels we found 24 h after MI. Several mechanisms might contribute to the enhanced cardiac leucocyte recruitment after injection of the MAGL inhibitor. Elevated systemic 2-AG levels might enhance myeloid cell mobilization from the bone marrow through a chemotactic effect, leading to increased cardiac recruitment. 11 Alternatively, 2-AG might promote inflammatory cytokine release in the heart as we found higher concentrations of neutrophil-recruiting CXCL1 and CXCL2 within the infarcted myocardium in MAGL inhibitor-treated mice. [34] [35] [36] However, this could also be a secondary consequence of enhanced neutrophil recruitment by 2-AG-mediated chemoattraction.
The increased neutrophil and monocyte-driven inflammation and MMP9 release in response to MAGL inhibition during the early phase 
after MI translated into a massive infarct. In the later infarct healing phase 7 days after ischaemia-reperfusion, MAGL inhibition led to increased numbers of cardiac macrophages of an inflammatory phenotype, which might be a consequence of the enhanced monocyte recruitment or a delay in inflammation resolution. 37 These cells are likely to contribute to an unfavourable cardiac wound healing, as observed in mice treated with JZL184. Interestingly, MAGL inhibition did not affect apoptotic cell numbers in the infarct, which could indicate that phagocytosis function, mainly promoted by M2 macrophages, is unaffected by 2-AG. The increased cardiac MMP9 protein levels in mice treated with MAGL inhibitor, associated with larger ventricular scar sizes of a poor quality, are in line with previous reports that MMP9 regulates pathologic cardiac remodelling processes. 38, 39 In particular, reduced density of collagen Type I fibres and a thinner left ventricular anterior wall thickness in MAGL inhibitor-treated mice results in fragile ventricular walls, which bear the risk of cardiac ruptures. 40, 41 This is in line with the higher mortality and increased incidence of cardiac rupture in mice receiving MAGL inhibitor compared with the vehicle group. The observation that excessive cardiac neutrophil infiltration into the heart of MAGL inhibitortreated mice leads to an increased infarct size, cardiac rupture and worsened cardiac function is also in agreement with our previously published findings that time-of-day-dependent fluctuations of circulating blood and tissue neutrophil counts critically affect MI healing responses. 40 Although endocannabinoid signalling per se might affect cardiovascular physiology, 42 MAGL inhibition did not affect heart rate and cardiac output after MI. However, MAGL inhibitor-treated mice suffered from more pronounced decline of ejection fractions 3-21 days after MI and ventricular dilatation 14-21 days post-MI compared with the vehicle group. Since timely revascularization is the gold standard of MI treatment, we aimed to verify our finding in a clinically more relevant myocardial ischaemia-reperfusion MI model. This model differs from the permanent ligation MI model as revascularization after ischaemia results in reperfusion injury, which originates, among other, from a massive leucocyte infiltration immediately after reopening coronary blood flow. 43 Similar to our (E) Flow cytometric quantification of macrophages in digested hearts 7 days after ischaemia-reperfusion (n = 6 mice). (F) Pie chart of the ratio between inflammatory macrophages (M1 MU; CD206-) and reparative macrophages (M2 MU; CD206þ) 7 days after ischaemia-reperfusion (n = 6 mice). (G) Representative images 7 days after ischaemia-reperfusion stained with Masson trichrome (blue, collagen; red, vital myocardium; Â20 magnification; scale bars represent 50 mm). (H) Quantification of fibrotic scar size relative to total LV area 7 days after ischaemia-reperfusion (n = 6 mice). Data were obtained in two independent experiments. All data are expressed as mean ± SEM; unpaired Student's t-test; *P < 0.05; two-way ANOVA followed by Bonferroni post hoc test (B and D) or unpaired Student's t-test (C, E, F, and H); *P < 0.05; ns, not significant. findings in the permanent ligation model, MAGL inhibition after ischaemia-reperfusion increased cardiac myeloid recruitment, which was accompanied by elevated plasma CXCL1 and cardiac MMP9 mRNA levels in the early inflammatory phase. Beyond the acute inflammatory phase, we noted a sustained presence of proinflammatory M1 macrophages in the myocardium and larger ventricular scar sizes. Although these preclinical observations need to be confirmed in larger animal models or clinical trials, our findings should raise awareness for the potential role of endocannabinoids in contributing to post-MI inflammation and outcome. Finally, it has to be considered that we performed this study only in female mice, because male mice in experimental MI models have a higher incidence of mortality due to cardiac rupture. The underlying cause for this gender difference in cardiac rupture involves higher severity of inflammation, MMP activation and damage to collagen matrix in males compared with females. 44 We believe that the use of female mice with a more moderate post-MI inflammatory response, lower incidence of mortality and thus lower number of mice to be used is more suitable for studying the causal implication of the 2AG/CB2 axis in this experimental model in accordance with the 3R guidelines. Nevertheless, it is certainly of crucial importance to consider gender differences when interpreting experimental and clinical data.
To conclude, our findings suggest that alterations of endocannabinoid 2-AG signalling via CB2 cannabinoid receptors affect leucocyte counts at steady state and after MI, which is of clinical importance as neutrophilia after MI is associated with a higher mortality and a poorer outcome. 45, 46 While various side effects of pharmaceutical drugs interfering with the endocannabinoid system have been reported, little is known about the effect of these drugs on the inflammatory system. Our work raises the concern that plant-derived or synthetic cannabinoids might affect leucocyte counts in patients with cardiovascular diseases thereby increasing their risk for adverse events and outcomes. Given the increasing consumption of plant derived and synthetic cannabinoids and the use of cannabinoids for a limited number of therapeutic applications, there is certainly a high interest for further investigations in this field.
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